Janus Henderson Group PLC Cuts Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX)

Janus Henderson Group PLC decreased its position in Arcellx, Inc. (NASDAQ:ACLX) by 1.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,522,309 shares of the company’s stock after selling 15,901 shares during the quarter. Janus Henderson Group PLC owned approximately 2.85% of Arcellx worth $105,856,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Perceptive Advisors LLC grew its position in Arcellx by 14.6% in the 4th quarter. Perceptive Advisors LLC now owns 4,544,809 shares of the company’s stock worth $252,237,000 after purchasing an additional 578,831 shares in the last quarter. Bamco Inc. NY grew its holdings in shares of Arcellx by 292.1% in the first quarter. Bamco Inc. NY now owns 248,993 shares of the company’s stock valued at $17,317,000 after acquiring an additional 185,493 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Arcellx by 8.1% during the first quarter. Vanguard Group Inc. now owns 2,228,856 shares of the company’s stock valued at $155,017,000 after acquiring an additional 167,037 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Arcellx by 200.6% during the fourth quarter. Federated Hermes Inc. now owns 214,599 shares of the company’s stock valued at $11,910,000 after acquiring an additional 143,212 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in Arcellx by 425.0% during the fourth quarter. Victory Capital Management Inc. now owns 155,652 shares of the company’s stock worth $8,639,000 after acquiring an additional 126,002 shares during the period. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Insiders Place Their Bets

In other news, insider Christopher Heery sold 10,901 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $65.30, for a total transaction of $711,835.30. Following the completion of the transaction, the insider now directly owns 9,278 shares in the company, valued at approximately $605,853.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Christopher Heery sold 10,901 shares of Arcellx stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $65.30, for a total transaction of $711,835.30. Following the completion of the sale, the insider now owns 9,278 shares of the company’s stock, valued at $605,853.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Michelle Gilson sold 12,121 shares of the company’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $50.71, for a total value of $614,655.91. Following the completion of the transaction, the chief financial officer now owns 19,792 shares in the company, valued at $1,003,652.32. The disclosure for this sale can be found here. Insiders have sold 91,070 shares of company stock worth $5,076,328 in the last three months. 6.24% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ACLX. HC Wainwright decreased their target price on Arcellx from $82.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 13th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Arcellx in a research report on Monday, July 22nd. Stifel Nicolaus boosted their target price on shares of Arcellx from $82.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, May 15th. Piper Sandler started coverage on shares of Arcellx in a research note on Friday, May 31st. They set an “overweight” rating and a $70.00 price target for the company. Finally, Truist Financial reiterated a “buy” rating and issued a $87.00 price objective on shares of Arcellx in a research note on Tuesday, June 18th. Thirteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $78.00.

Arcellx Trading Up 1.0 %

Shares of NASDAQ ACLX traded up $0.64 during mid-day trading on Wednesday, hitting $62.31. The company had a trading volume of 34,506 shares, compared to its average volume of 453,355. Arcellx, Inc. has a 1 year low of $30.88 and a 1 year high of $75.10. The company has a market capitalization of $3.33 billion, a price-to-earnings ratio of -59.87 and a beta of 0.23. The stock’s 50-day moving average price is $56.28 and its 200-day moving average price is $59.26.

Arcellx (NASDAQ:ACLX) last posted its earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.37. Arcellx had a negative return on equity of 13.11% and a negative net margin of 38.39%. The business had revenue of $39.26 million during the quarter, compared to analyst estimates of $20.67 million. During the same quarter in the previous year, the firm earned ($0.58) EPS. The company’s quarterly revenue was up 119.2% compared to the same quarter last year. As a group, equities research analysts forecast that Arcellx, Inc. will post -1.7 earnings per share for the current year.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).